Compass Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 32
- Market Cap
- $173.3M
- Introduction
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery, human display for antibody tuning, stitchmabs, and highly modular and manufacturable bispecific candidates. The company was founded by Thomas J. Schuetz in 2014 and is headquartered in Boston, MA.
Commit Biologics Forms Scientific Advisory Board to Advance Complement-Based Cancer and Autoimmune Therapies
Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.
Compass Therapeutics Advances Pipeline with New Bispecific Antibody Candidate
Compass Therapeutics is set to release Phase 2/3 data for tovecimig in biliary tract cancer by the end of Q1 2025, marking a key milestone.
Compass Therapeutics' CTX-471 Shows Promise with NCAM Biomarker Correlation in Advanced Malignancies
Compass Therapeutics presented data at SITC showing a significant correlation between NCAM expression and patient response to CTX-471 monotherapy.